Subependymal giant cell astrocytoma: a clinicopathological study of 23 cases with special emphasis on proliferative markers and expression of p53 and retinoblastoma gene proteins

References

• Shepherd CW, Scheithauer BW, Gomez MR, Altermatt HJ, Katzmann JA. Subependymal giant cell astrocytoma: a clinical, pathological and flow cytometric study. Neurosurgery 1991; 28: 864–8.
   Google Scholar
• Halmagyi GM, Bignold LP, Allsop JL. Recurrent subependymal giant cell astrocytoma in the absence of tuberous sclerosis. J Neurosurg 1979; 50: 105–9.
   Google Scholar
• Bonnin JM, Rubinstein Li, Papasozomenos S, Marangos Pi. Subependymal giant cell astrocytoma: significant and possible cytogenetic implications of an immunohistochemical study. Acta Neuropathol (Berl) 1984; 62: 185–93.
   PubMed Web of Science ®Google Scholar
• Fuziwara S, Takaki T, Hikita T, Nishio S. Subependymal giant cell astrocytoma associated with tuberous sclerosis: do subependymal nodules grow? Childs Nerv Syst 1989; 5: 43–4.
   PubMed Web of Science ®Google Scholar
• Morimoto K, Mogani H. Sequential CT study of subependymal giant cell astrocytoma associated with tuberous sclerosis: case report. J Neurosurg 1986; 65: 874–7.
   PubMed Web of Science ®Google Scholar
• Chow CW, Klug GL, Lewis EA. Subependymal giant cell astro-cytoma in children: an unusual discrepancy between histological and clinical features. Neurosurgery 1988; 68: 880–3.
   Google Scholar
• Padmalatha C, Harruff RC, Ganick D, Hafez GR. Glioblastoma multiforme with tuberous sclerosis: report of a case. Arch Pathol Lab Med 1980; 105: 645–50.
   Google Scholar
• Brown JM. Tuberous sclerosis with malignant astrocytoma. Med J Aust 1975; 1: 811–4.
   PubMed Web of Science ®Google Scholar
• Boesel CP, Paulson GW, Kosnik EJ, Earle KM. Brain hamartomas and tumors associated with tuberous sclerosis. Neurosurgery 1979; 4: 410–7.
   PubMed Web of Science ®Google Scholar
• von Deimling A, Eibl RH, Ohgaki H, et al. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytomas. Cancer Res 1992; 52: 2987–90.
   PubMed Web of Science ®Google Scholar
• Rasheed BK, McLendon RE, Herndon JE, et al. Alterations of the TP53 gene in human gliomas. Cancer Res 1994; 54: 1324–30.
   PubMed Web of Science ®Google Scholar
• Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992; 355: 846–7.
   PubMed Web of Science ®Google Scholar
• Bogler O, Huang Hi, Kleihues P, Cavenee WK. The p53 gene and its role in human brain tumors. Glia 1995; 15: 308–27.
   PubMed Web of Science ®Google Scholar
• Henson JW, Schnitker BL, Correa KM, et al. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 1994; 36: 714–21.
   PubMed Web of Science ®Google Scholar
• James CD, Carlbom E, Dumanski JP, et al. Clonal genomic alterations in glioma malignancy stages. Cancer Res 1988; 48: 5546–51.
   PubMed Web of Science ®Google Scholar
• Ellison DW, Steart PV, Bateman AC, Pickering RM, Palmer JD, Weller RO. Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psychiatry 1995; 59: 413–9.
   PubMed Web of Science ®Google Scholar
• Kurki P, Vanderlaan M, Dolbeare F, Gray J, Tan EM. Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res 1986; 166: 209–19.
   PubMed Web of Science ®Google Scholar
• Holm C, Stearns T, Botstein D. DNA topoisomerase II must act at mitoses to prevent nondisjunction and chromosome breakage. Mol Cell Biol 1989; 9: 159–68.
   Google Scholar
• Lynch BJ, Guinee DG Jr, Holden JA. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Hum Pathol 1997; 28: 1180–8.
   PubMed Web of Science ®Google Scholar
• Brandes AA, Rigon A, Zampieri P, et al. Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multi-forme: a phase II study. Cancer 1998; 82: 355–61.
   PubMed Web of Science ®Google Scholar
• Jay V, Edwards V, Rutka JT. Crystalline inclusions in a subependy-mal giant cell tumor in a patient with tuberous sclerosis. Ultrastruct Pathol 1993; 17: 503–13.
   Google Scholar
• Gyure KA, Prayson RA. Subependymal giant cell astrocytoma: a clinicopathologic study with HMB-45 and MIB-1 immunohistochem-ical analysis. Mod Pathol 1997; 10: 313–7.
   PubMed Web of Science ®Google Scholar
• Kim SK, Wang KC, Cho BK, et al. Biological behavior and tumorigenesis of subependymal giant cell astrocytomas. J Neurooncol 2001; 52: 217–25.
   PubMed Web of Science ®Google Scholar
• Kingsley DPE, Kendall BE, Fitz CR. Tuberous sclerosis: a clinicoradiological evaluation of 110 cases with particular reference to atypical presentations. Neuroradiol 1986; 28: 38–46.
   Google Scholar
• Karamitopoulou E, Perentes E, Diamantis J, Maraziotis J. Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB-1 monoclonal antibody on archival material. Acta Neuropathol 1994; 87: 47–54.
   PubMed Web of Science ®Google Scholar
• Louis DN, Edgerton S, Thor AD, Hedley-Whyte ET. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study. Acta Neuropathol (Berl) 1991; 81: 675–9.
   Google Scholar
• Heck MMS, Earnshaw WC. Topoisomerase II: a specific marker for cell proliferation. J Cell Biol 1986; 103: 2568–81.
   Web of Science ®Google Scholar
• Cunningham JM, Kimmel DW, Scheithauer BW, O'Fallon JR, Novotny Pi, Jenkins RB. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg 1997; 86: 121–30.
   Google Scholar
• Battifora H. p53 immunohistochemistry: a word of caution. Hum Pathol 1994; 25: 435–7.
   PubMed Web of Science ®Google Scholar